Genfit: profit-taking after clinical trial results announcement

Genfit recorded a technical correction on June 4, 2026 following investor profit-taking after the announcement of encouraging clinical trial results.

Published 9sem1 sourceupdated 13h

Lire en français

≈ 20sSpeed

The fact

This volatility is typical for small-cap biotechs in therapeutic development phase.

Analyses remain favorable to the biotech's potential in hepatic disease screening.

Click the link to read an article on the topic:

Boursorama

Explore this topic

France Genfit #Genfit #biotech #essais cliniques #bénéfices

What if you saw the whole news differently?Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page.

FranceWorld map →

Follow topic →

Auto-synthesis from 1 media source · identified on June 8, 2026

← Back to home

The fact

Read more

Genfit: French biotech status on April 12, 2026

Genfit plummets after clinical trial failure

Genfit attempts a rebound after months of decline

Genfit updates its GNS561 clinical study, shareholders react

Genfit under pressure following volatile trading session

Genfit closes steady at 13 euros, awaiting catalysts